Wortmannin NEW
| Price | $32 | $45 | $72 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Wortmannin | CAS No.: 19545-26-7 |
| Purity: 99.76% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Wortmannin |
| Description | Wortmannin (SL-2052) is a PI3K inhibitor (IC50=3 nM) that is covalent and irreversible. Wortmannin is also an inhibitor of PlK1 and PlK3 (IC50=5.8/48 nM) that blocks autophagy. |
| In vitro | METHODS: Human breast cancer cells MCF-7 were treated with Wortmannin (50-500 nM) for 24 h. Cell death was detected by Trypan blue exclusion assay. RESULTS: Wortmannin induced cell death in MCF-7 cells in a concentration-dependent manner with an IC50 of 400 nM. [1] METHODS: Human breast cancer cells MCF-7 were treated with Wortmannin (6.25-50 nM) for 24 h. The expression levels of target proteins were detected by Western Blot. RESULTS: Concentration-dependent reduction of p-Akt and NF-κB p65 expression was induced by Wortmannin. [2] |
| In vivo | METHODS: To determine whether activation of the insulin pathway and brain enlargement were responsible for fatal seizures, Wortmannin (1.5 mg/kg) was administered orally to Pcmt1-/- mice once a day for twenty-two days. RESULTS: Wortmannin reduced the average brain size of Pcmt1-/- mice to within 6% of that of controls and nearly doubled the lifespan of Pcmt1-/- mice, with a survival rate of 60% of the original population. [3] METHODS: To investigate antitumor activity, Wortmannin (0.25-1 mg/kg) was injected intravenously three times a week for three weeks into SCID mice bearing the human breast cancer tumor MDA-MB-231. RESULTS: Wortmannin significantly inhibited tumor metastasis and angiogenesis. [4] |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 2.1 mg/mL (5 mM)), Heating is recommended. DMSO : 21.4 mg/mL (50 mM) |
| Keywords | KY12420 | Antibiotic | SL 2052 | PI3K | inhibit | Wortmannin | Autophagy | Polo-like Kinase (PLK) | KY 12420 | Phosphoinositide 3-kinase | Inhibitor | SL2052 |
| Inhibitors Related | Neomycin sulfate | Stavudine | Ampicillin sodium | Kanamycin sulfate | Sulfamethoxazole sodium | Hydroxychloroquine | Guanidine hydrochloride | Doxycycline | Paeonol | Naringin |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Autophagy Compound Library | Inhibitor Library | Microbial Natural Product Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2.00/1kg |
VIP7Y
|
Career Henan Chemical Co
|
2018-12-24 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY